Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.
Bosco EE, Christie RJ, Carrasco R, Sabol D, Zha J, DaCosta K, Brown L, Kennedy M, Meekin J, Phipps S, Ayriss J, Du Q, Bezabeh B, Chowdhury P, Breen S, Chen C, Reed M, Hinrichs M, Zhong H, Xiao Z, Dixit R, Herbst R, Tice DA.
Bosco EE, et al.
Oncotarget. 2018 May 1;9(33):22960-22975. doi: 10.18632/oncotarget.25160. eCollection 2018 May 1.
Oncotarget. 2018.
PMID: 29796165
Free PMC article.
Despite recent advances in treatment, breast cancer remains the second-most common cause of cancer death among American women. ...Immunohistochemistry (IHC) revealed that GFRA1 displays a limited normal tissue expression profile coupled with overexpression in …
Despite recent advances in treatment, breast cancer remains the second-most common cause of cancer death among American women. …